Clinical trial · Interventional
Biomolecular Markers of Bone Metastasis
NCT06806462CI-TRIAL-00085497recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to characterize the biomolecular profile of bone metastases to define the predisposing profiles of bone metastasis, in patients with breast or lung or renal carcinomas or of the gastroenteric or prostate tract with bone metastasis. The main question it aims to answer is: Is it possible to predict the progression of bone metastasis by identifying biomarkers as risk factors for bone metastasis?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biomolecular profile of bone metastases | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Bone metastasis
- description
- Patients with breast or lung or renal or gastroenteric tract or prostate carcinomas with bone metastases
- interventionNames
- Genetic: Biomolecular profile of bone metastases
Primary outcomes (2)
- measure
- Bone metastasis profiling
- timeFrame
- up to 100 weeks
- description
- Characterizing the biomolecular profile of bone metastasis to define the predisposing profiles of bone metastasis. Transcriptional profile of * RANK/RANKL * OPG * PTHLH * IL-1/6/7/8/11, * TNF-alfa
- measure
- Fracture pathological profiling
- timeFrame
- up to 100 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>= 18 years * Patients with breast or lung or renal or gastroenteric tract or prostate with bone metastases * Patients who knowingly express willingness to participate in the study after signing the written informed consent Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.